Equillium, Inc. - Common Stock (OQ:EQ)

Business Focus: N/A

Get the company report for the most recent outlook updated daily

May 07, 2024 08:00 am ET

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that a poster was presented at IMMUNOLOGY2024, the annual meeting of The American Association of Immunologists. The meetings are taking place at McCormick Place Convention Cente

Apr 03, 2024 08:00 am ET

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on April 1, 2024, the Compensation Committee of Equillium’s Board of Directors granted an inducement award consisting of a nonstatutory stock option to purchase 10,000 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan. The Compensation Committee approved the stock option as an inducement material to the new employee’s employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Apr 01, 2024 08:00 am ET

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced positive topline data from the Type B portion of the Phase 1b EQUALISE study evaluating itolizumab in lupus nephritis patients. The data suggests

Mar 28, 2024 09:31 am ET

Thinking about buying stock in Braze, Velo3D, InterCure, Equillium, or Bioatla?

NEW YORK, March 28, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BRZE, VLD, INCR, EQ, and BCAB.

Mar 27, 2024 09:31 am ET

Thinking about trading options or stock in Advanced Micro Devices, Equillium, Macy's, Alphabet, or Phillips 66?

NEW YORK, March 27, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, EQ, M, GOOGL, and PSX.

Mar 26, 2024 09:31 am ET

Thinking about buying stock in Equillium, Kuke Music, Altamira Therapeutics, MoneyHero, or Enerplus?

NEW YORK, March 26, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EQ, KUKE, CYTO, MNY, and ERF.

Mar 25, 2024 04:01 pm ET

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the fourth quarter and full year 2023, as well as corporate and clinical highlights.

Mar 22, 2024 08:00 am ET

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference, and the LD Micro Invitational Conference.

Dec 21, 2023 08:00 am ET

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced an update on multi-cytokine programs EQ101 in development for the treatment of alopecia areata, EQ102 in development for the treatment of celiac d

Nov 20, 2023 10:23 am ET

EQ Bank Card launches in Québec as Carte Banque EQ

Popular bank card gives customers the ability to earn, save, and spend their money

Nov 20, 2023 10:23 am ET

EQ Bank Card launches in Québec as Carte Banque EQ

Popular bank card gives customers the ability to earn, save, and spend their money

Nov 13, 2023 09:00 am ET

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that data from the Type B portion of the EQUALISE study evaluating itolizumab in lupus nephritis patients was presented at ACR Convergence, the annual mee

Nov 08, 2023 04:01 pm ET

Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter 2023 and provided corporate and clinical development updates.

Nov 06, 2023 08:00 am ET

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that data from the Type B portion of the EQUALISE study in lupus nephritis patients was presented at the annual meeting of the American Society of Nephrol

Oct 19, 2023 08:00 am ET

Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that abstracts were accepted for poster presentations at the annual meetings of the American Society of Nephrology (ASN) and the American College of Rheumatology (ACR).

Oct 16, 2023 08:00 am ET

Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium

Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced a presentation at the 18th Annual Peptide Therapeutics Symposium highlighting EQ302, a second generation orally deliverable multi-cytokine inhibitor i

Oct 03, 2023 08:00 am ET

Equillium to Host Analyst & Investor Day

Oct 02, 2023 08:00 am ET

Equillium to Present at the JonesTrading 2023 Healthcare Summit

Sep 20, 2023 08:00 am ET

Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences

Aug 30, 2023 08:00 am ET

Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will host investor meetings at the Wells Fargo Healthcare Conference, and present and host meetings

Aug 09, 2023 04:01 pm ET

Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the second quarter 2023 and provided corporate and clinical devel

Aug 02, 2023 04:00 pm ET

Equillium Announces $7.5 Million Share Repurchase Program

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that its Board of Directors authorized the repurchase of up to $7.5 million of shares of the Company’s commo

Jun 01, 2023 08:00 am ET

Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the Jefferies Global Healthcare Conference and the LD Micro Invitational Conference.

May 15, 2023 08:00 am ET

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced a poster was presented over the weekend at IMMUNOLOGY2023, the annual meeting of The American Association of I

May 11, 2023 04:01 pm ET

Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the first quarter 2023 and provided corporate and clinical development updates.

Apr 24, 2023 08:00 am ET

Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that an ePoster presentation highlighting data from the EQUATE study in acute graft-versus-host diseas

Mar 23, 2023 04:01 pm ET

Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the fourth quarter and full year 2022 and provided corporate and clinical development updates.

Mar 22, 2023 08:00 am ET

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference

Feb 17, 2023 08:00 am ET

Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an oral presentation was given yesterday afternoon at the Tandem Meetings of the American Society of Transplantation and Cellular Therapy, and the Center for Intern

Feb 07, 2023 08:00 am ET

Equillium to Present at the SVB Securities Annual Global Healthcare Conference

Jan 13, 2023 08:00 am ET

Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an abstract was accepted for oral presentation at the Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy, a

Dec 23, 2022 04:01 pm ET

Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement

Equillium, Inc. (Nasdaq: EQ) and Metacrine, Inc. today announced the mutual termination of their previously announced definitive merger agreement.

Dec 16, 2022 08:00 am ET

Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Biocon Limited, in collaboration with Equillium, has initiated a Phase 2 clinical study of itolizumab in patients with ulcerative colitis (UC).

Dec 14, 2022 10:29 am ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MVBF, EQ, MTCR, SESN

NEW YORK, Dec. 14, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Dec 13, 2022 05:14 pm ET

SHAREHOLDER ALERT: Weiss Law Reminds EQ, IMGO, MTCR, and OPNT Shareholders About Its Ongoing Investigations

NEW YORK, Dec. 13, 2022 /PRNewswire/ --

Dec 07, 2022 11:32 pm ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SBCF, PFHD, EQ, MTCR

NEW YORK , Dec. 8, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Dec 07, 2022 02:34 pm ET

SHAREHOLDER ALERT: Weiss Law Reminds EQ, IMGO, MTCR, and OPNT Shareholders About Its Ongoing Investigations

NEW YORK, Dec. 7, 2022 /PRNewswire/ --

Dec 06, 2022 07:00 am ET

Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, and Ono Pharmaceutical Co., Ltd. (“Ono”), today announced an option and asset purchase agreement through which Ono gains the exclusive option to purchase Equillium’s rights to itolizumab, a first-in-class monoclonal antibody targeting CD6. These rights include all therapeutic indications and the rights to commercialize itolizumab in the United States, Canada, Australia, and New Zealand.

Dec 01, 2022 10:45 am ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EQ, MTCR, TALO, SSNT

NEW YORK, Dec. 1, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Nov 30, 2022 09:15 pm ET

SHAREHOLDER ALERT: Weiss Law Reminds EQ, IMGO, MTCR, and OPNT Shareholders About Its Ongoing Investigations

NEW YORK, Nov. 30, 2022 /PRNewswire/ --

Nov 24, 2022 11:17 am ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EQ, MTCR, KNBE, IMRA

NEW YORK, Nov. 24, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Nov 23, 2022 06:51 pm ET

SHAREHOLDER ALERT: Weiss Law Investigates Equillium, Inc.

NEW YORK,, Nov. 23, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Equillium, Inc. ("Equillium" or the "Company") (NASDAQ: EQ), in connection with its takeover of Metacrine, Inc. (Metacrine) (NASDAQ: MTCR). Under the terms of the merger agreement, Equillium will issue stock valued at a 25% premium over the Metacrine net cash delivered at closing, which is estimated to be approximately $26 million.

Nov 23, 2022 11:37 am ET

SHAREHOLDER ALERT: Weiss Law Investigates Metacrine, Inc.

NEW YORK, Nov. 23, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Metacrine, Inc. ("Metacrine" or the "Company") (NASDAQ: MTCR), in connection with the acquisition of the Company by Equillium, Inc. ("Equillium") (NASDAQ: EQ). Under the terms of the merger agreement, Equillium will issue stock valued at a 25% premium over the net cash delivered at closing, which is estimated to be approximately $26 million.

Nov 14, 2022 04:01 pm ET

Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the third quarter 2022 and provided an update on its clinical development programs.

Nov 14, 2022 08:00 am ET

Equillium Announces Data Suggesting Soluble ALCAM as a Potential Biomarker of Disease Severity in Lupus Nephritis at ACR Convergence 2022

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that a poster presentation was given over the weekend at ACR Convergence, the annual meeting of the American College of Rheumatology. The presentation highlighted that levels of urinary soluble ALCAM (sALCAM) could be a potential biomarker of disease severity in lupus nephritis (LN) and indicative of a patient’s response to treatment. The meeting, the world’s premier rheumatology confere

Nov 11, 2022 08:58 pm ET

METACRINE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Metacrine Inc. - MTCR

NEW ORLEANS, Nov. 11, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of Metacrine Inc. (NasdaqCM: MTCR) (the "Company") with Equillium, Inc. (NasdaqGM: EQ) in an all-stock transaction. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.

Nov 10, 2022 09:50 am ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EQ, STR, MNRL, STOR

NEW YORK, Nov. 10, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Nov 10, 2022 08:00 am ET

Equillium Announces Initiation of Phase 2 study of EQ101 A First-in-Class Multi-Cytokine Inhibitor of IL-2, IL-9 and IL-15 Targeting Alopecia Areata

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it has initiated a Phase 2 open-label study of EQ101 to assess efficacy and safety in adult subjects with moderate to severe alopecia areata. The study is expected to enroll approximately 30 subjects at multiple clinical sites in Australia.

Nov 08, 2022 08:00 am ET

Equillium to Present at Two Upcoming Investor Conferences

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will participate in fireside chat presentations at the Stifel Healthcare Conference and the Jefferies London Healthcare Conference.

Nov 03, 2022 08:00 am ET

Equillium Announces Presentation at the 6th Annual Dermatology Drug Development Summit

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced a presentation at the 6th Annual Dermatology Drug Development Summit. The presentation highlights Equillium’s Multi-Cytokine Inhibitor EQ101 as a novel molecular compound to treat alopecia areata. Data on the first-in-class tri-specific inhibitor, targeting Il-2, IL-9 and IL-15, were presented by Dr. Stephen Connelly, co-founder and chief scientific officer of Equillium. The S

Nov 02, 2022 08:00 am ET

Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it has initiated a Phase 1 study of EQ102 in healthy volunteers, completed dosing of the initial cohort of eight study participants and begun dosing the second cohort.

Oct 28, 2022 11:25 am ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EQ, RCKT, RMED, RCOR

NEW YORK, Oct. 28, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Oct 27, 2022 07:14 pm ET

INVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of Equillium, Inc. - EQ

NEW YORK, Oct. 27, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Equillium, Inc. (EQ), relating to its proposed merger with Metacrine Inc. Click here for more information: https://www.monteverdelaw.com/case/equillium-inc. It is free and there is no cost or obligation to you.

Oct 26, 2022 08:00 am ET

Equillium Announces Presentation of Data Demonstrating Biological Importance of Multi-Cytokine Inhibitors EQ101 and EQ102 at the La Jolla Immunology Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced data presented at the annual La Jolla Immunology Conference. The research highlights the potential for multi-cytokine inhibitors such as EQ101 and EQ102, as potentially effective strategies for the treatment of certain autoimmune diseases.

Oct 18, 2022 11:35 am ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNBE, CYBE, EQ, MNRL, RMED

NEW YORK, Oct. 18, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Sep 30, 2022 07:15 am ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EQ, MTCR, BTRS, PZN

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Equillium, Inc. (NASDAQ: EQ)’s merger...

Sep 27, 2022 08:30 am ET

Thinking about buying stock in Equillium, Marathon Digital, Missfresh, Ocular Therapeutix, or Riot Blockchain?

NEW YORK, Sept. 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EQ, MARA, MF, OCUL, and RIOT.

Sep 27, 2022 07:00 am ET

Equillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced interim results from the Type B portion of the EQUALISE study evaluating itolizumab, a first-in-class anti-CD6 monoclonal antibody selectively targeting the CD6-ALCAM pathway, in patients with lupus nephritis (LN).

Sep 26, 2022 12:00 am ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EQ, MTCR, STOR, RCKT

NEW YORK, Sept. 26, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Sep 22, 2022 07:31 am ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMTX, SMBC, EQ, MTCR

Sep 19, 2022 01:48 am ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ECOM, SGFY, EQ, MTCR

NEW YORK, Sept. 19, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Sep 15, 2022 08:00 am ET

Equillium Announces Abstract Accepted for Presentation at ACR Convergence 2022

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that an abstract was accepted for presentation at ACR Convergence, the annual meeting of the American College of Rheumatology. The meeting, the world’s premier virtual rheumatology experience, will take place online November 10 – 14, 2022 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.

Sep 12, 2022 12:00 am ET

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates CYBE, SBET, MNRL, EQ

Sep 07, 2022 08:02 am ET

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates STR, MNRL, EQ, MTCR

Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Sitio Royalties Corp. (NYSE: STR)’s...

Sep 06, 2022 06:34 pm ET

EQ Stock Alert: Halper Sadeh LLP is Investigating Whether the Merger of Equillium, Inc. is Fair to Shareholders

Halper Sadeh LLP, an investor rights law firm, is investigating whether the merger of Equillium, Inc. (NASDAQ: EQ) and Metacrine Inc. is fair to Equillium shareholders.

Sep 06, 2022 04:00 pm ET

Equillium to Acquire Metacrine in All-Stock Transaction

Equillium, Inc. (Nasdaq: EQ) and Metacrine Inc. (Nasdaq: MTCR), today announced that the two companies have entered into a definitive merger agreement pursuant to which Equillium will acquire Metacrine in an all-stock transaction. The transaction is anticipated to add $33 million in cash to Equillium’s balance sheet at closing, which is expected to extend the company’s cash runway into 2024. The transaction has been approved by the boards of directors of both companies.

Aug 31, 2022 08:00 am ET

Equillium to Present at Two Upcoming Investor Conferences

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will participate in a fireside chat presentation at the Wells Fargo Healthcare Conference and a corporate presentation at the H.C. Wainwright Annual Global Investment Conference.

Aug 15, 2022 04:01 pm ET

Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development Updates

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the second quarter 2022 and provided an update on its clinical development programs.

Jul 28, 2022 08:00 am ET

Equillium Announces Presentation at the 3rd Annual Cytokine-Based Drug Development Summit

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced a presentation at the 3rd Annual Cytokine-Based Drug Development Summit. The presentation highlights Equillium’s multi-cytokine inhibitor technology and platform, and applications of cytokine technology beyond oncology. Data on the platform, including the lead tri-specific inhibitory agent, EQ101, were presented by Dr. Stephen Connelly, co-founder and chief scientific officer of Equilliu

May 17, 2022 08:00 am ET

Equillium to Present at Two Upcoming Investor Conferences

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will be presenting at the H.C. Wainwright Global Investment Conference and the Jefferies Healthcare Conference.

May 12, 2022 04:01 pm ET

Equillium Reports First Quarter 2022 Financial Results and Provides Corporate and Clinical Development Updates

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the first quarter 2022 and provided an update on its corporate development and clinical programs.

May 12, 2022 08:00 am ET

Equillium Announces Publication of Abstract for the Annual Congress of the European Hematology Association

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that the European Hematology Association (EHA) has published an abstract highlighting the Phase 3 EQUATOR study in first-line acute graft-versus-host disease (aGVHD).

May 09, 2022 08:00 am ET

Equillium Announces Three Poster Presentations at the Annual Meeting of The American Association of Immunologists

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that three posters were presented over the weekend at IMMUNOLOGY2022, the annual meeting of The American Association of Immunologists. The meetings are taking place at the Oregon Convention Center in Portland, Oregon, May 6 – 10, 2022.

Apr 25, 2022 08:00 am ET

Equillium Announces Three Poster Presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTR

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that three posters were presented over the weekend at the Transplantation & Cellular Meetings of the American Society of Transplantation and Cellular Therapy, and the Center for International Blood & Marrow Transplant Research. The hybrid meetings are taking place virtually and in-person at the Salt Palace Convention Center in Salt Lake City, April 23 – 26, 2022.

Apr 04, 2022 08:00 am ET

Equillium Announces Oral Presentation at the Italian Society of Experimental Hematology

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced an oral presentation at the 2022 National Congress of the Italian Society of Experimental Hematology in Rome, Italy. The presentation analyzes data from the immune reconstitution of 95 adult patients that underwent allogeneic hematopoietic cell transplantations at the Dana-Farber Cancer Institute between September 2018 and January 2020, demonstrating itolizumab’s ability to inhibit patho

Mar 23, 2022 04:01 pm ET

Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development Updates

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the fourth quarter and full year 2021 and provided corporate and clinical development updates.

Mar 23, 2022 01:42 pm ET

Equillium Announces Two Oral Presentations at the Annual Meeting of the European Society for Blood and Marrow Transplantation

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced two oral presentations at the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation. The presentations include new findings demonstrating durability of clinical response out to one year for patients with high-risk acute graft-versus-host disease (aGVHD) that were treated with itolizumab in the EQUATE study. Clinical data were presented by Corey Cutler, M.D., as

Mar 04, 2022 08:00 am ET

Equillium Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced the initiation of the EQUATOR study, a pivotal Phase 3 clinical study of itolizumab in patients with acute graft-versus-host disease (aGVHD). The randomized, double-blind study will assess the efficacy and safety of itolizumab versus placebo as a first-line therapy for aGVHD in combination with corticosteroids. The primary objective of the study is to achieve early disease response, with

Mar 01, 2022 08:00 am ET

Equillium Announces Appointment of Barbara Troupin to Board of Directors

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced the appointment of Barbara Troupin, M.D., to the Equillium Board of Directors. Dr. Troupin will serve as a member of the Nominating and Corporate Governance Committee of the Board.

Feb 16, 2022 07:00 am ET

Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it has acquired Bioniz Therapeutics, Inc., a privately held clinical-stage biotechnology company. Bioniz developed its novel structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from its proprietary product discovery platform. The Bioniz lead product candidates are multi-specific inhibitors of key disease-driving, clinically validated cytokine targets aimed at ad

Feb 15, 2022 08:00 am ET

Equillium Provides Timing Update on Conference Presentations

Feb 09, 2022 08:00 am ET

Equillium to Present at the SVB Leerink Virtual Global Healthcare Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will participate in a fireside chat presentation at the SVB Leerink Virtual Global Healthcare Conference, taking place February 14 – 18, 2022.

Jan 10, 2022 08:00 am ET

Equillium Announces Multiple Abstracts Accepted for Presentation at the Transplantation & Cellular Meetings of ASTCT and CIBMTR

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that three abstracts were accepted for presentation at the Transplantation & Cellular Meetings of the American Society of Transplantation and Cellular Therapy,

Jan 05, 2022 08:00 am ET

Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that Bruce Steel, Equillium’s chief executive officer, will present at the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available on January 10, 2022, at 7:00 am EST.

Jan 04, 2022 12:48 pm ET

Equillium Announces Publication of Data in the Journal of Clinical Investigation Highlighting the Importance of the CD6-ALCAM Pathway in the Pathogenesis of Lupus Nephritis

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced publication of a manuscript featured on the front cover of the Journal of Clinical Investigation (www.jci.org), confirming the role of T cells activated by the CD6-ALCAM path

Jan 04, 2022 08:00 am ET

Equillium Announces Data from Phase 1b EQUIP Study in Patients with Uncontrolled Asthma

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that the Phase 1b EQUIP study of itolizumab in patients with uncontrolled asthma met its primary objective of safety and tolerability and demonstrated on-target peak and sustained reduction of CD6 at Day 85 (one month following last dose). Itolizumab is a first-in-class anti-CD6 monoclonal antibody that targets the CD6-ALCAM signaling pathway to selectively inhibit pathogenic T effector cells.

Jan 04, 2022 08:00 am ET

Equillium Announces Publication of Data in the Journal of Clinical Investigation Highlighting the Importance of the CD6-ALCAM Pathway in the Pathogenesis of Lupus Nephritis

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced publication of a manuscript featured on the front cover of the Journal of Clinical Investigation (www.jci.org/this-month), confirming the role of T

Dec 13, 2021 08:00 am ET

Equillium Announces Additional Patient Data at ASH 2021 Demonstrating Continued Positive and Durable Clinical Responses in Acute Graft-Versus-Host Disease Patients Treated with Itolizumab

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced two poster presentations at the 63rd Annual Meeting of the American Society of Hematology (ASH), including additional patient data from EQUATE Phase 1b study in acute graft-versus-host disease (aGVHD) demonstrating a continued positive clinical impact on patients treated with itolizumab. Data collected at six months, at least four months after each patient’s last dose of itolizumab, showed that

Nov 10, 2021 04:01 pm ET

Equillium Reports Third Quarter 2021 Financial Results and Provides Clinical Development Updates

Nov 09, 2021 08:00 am ET

Equillium to Present at Two Upcoming Investor Conferences

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will participate in fireside chat presentations at the Stifel 2021 Virtual Healthcare Conference and the Jefferies Virtual London Healthcare Conference.

Nov 05, 2021 08:00 am ET

Equillium Presents Clinical Data from EQUALISE Phase 1b Study in Lupus Patients at the American Society of Nephrology Annual Meeting

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced interim data from the Type A portion of the Phase 1b EQUALISE study that showed promising clinical activity in patients with systemic lupus erythematosus (SLE), and pharmacokinetic and pharmacodynamic data supporting the anti-CD6 mechanism of itolizumab. The data were presented in two separate posters, both by Chaim Putterman, M.D., Professor of Medicine, Albert Einstein College of Medicine, at the America

Nov 05, 2021 08:00 am ET

Equillium Presents Interim Safety Data from First Cohort of Asthma Patients in Phase 1b EQUIP Study at the American College of Allergy, Asthma & Immunology Meeting

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today reported interim data from the first cohort in its randomized, placebo-controlled Phase 1b EQUIP study for itolizumab in patients with moderate to severe uncontrolled asthma. These data, which summarize early safety and clinical activity, are part of a poster presentation available to registered attendees of the hybrid, in-person/virtual, American College of Allergy, Asthma & Immunology meeting being held in New Orl

Nov 04, 2021 09:00 am ET

Equillium Announces Two Abstracts Accepted for Presentation at the 63rd ASH Annual Meeting and Exposition

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that two abstracts were accepted for presentation at the 63rd annual meeting of the American Society of Hematology to be held both in person and virtually, December 11 - 14, 2021.

Nov 02, 2021 08:00 am ET

Equillium Announces Interim Safety Data and Reduction in Proteinuria for Lupus Patients Treated with Itolizumab in the EQUALISE Study Presented at the ACR Annual Meeting

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that positive interim data from the Type A portion of the EQUALISE study in systemic lupus erythematosus (SLE) patients were presented in a poster session at the American College of Rheumatology (ACR) annual meeting. The data in poster #1750, authored by Kenneth Kalunian, M.D., professor of Medicine, at University of California San Diego School of Medicine, showed that itolizumab administration was well to

Oct 18, 2021 08:00 am ET

Equillium Announces Two Abstracts Accepted for Presentation at the Upcoming Virtual 2021 American Society of Nephrology Annual Meeting

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that two abstracts were accepted for presentation at the virtual 2021 American Society of Nephrology (ASN) Annual Meeting to be held November 4-7, 2021.

Sep 30, 2021 08:00 am ET

Equillium Announces Multiple Abstracts Accepted for Presentation at ACR Convergence 2021

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that three abstracts were accepted for presentation at ACR Convergence, the annual meeting of the American College of Rheumatology. The meeting, the world’s premier virtual rheumatology experience, will take place online November 3 - 10.

Sep 22, 2021 08:00 am ET

Equillium to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will participate in a fireside chat presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference, taking place September 27 – 30, 2021.

Sep 08, 2021 08:00 am ET

Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference, taking place September 13 – 15, 2021. The virtual on-demand presentation will be available as of Monday, September 13, 2021, at 7:00 am ET.

Aug 11, 2021 04:00 pm ET

Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced additional data from the EQUALISE Type A portion of the study in systemic lupus erythematosus (SLE) patients. The exploratory data set shows that patients without a diagnosis of lupus nephritis (LN) but with elevated urine protein/creatine ratio (UPCR) >200 mg/g (N=6, baseline geometric mean 378 mg/g)1 experienced a mean decrease from baseline in UPCR of 33% and 42% at Days 29 and 57 respectivel

Aug 10, 2021 04:01 pm ET

Equillium Reports Second Quarter 2021 Financial Results and Provides Clinical Development Update

Aug 05, 2021 08:00 am ET

Equillium to Present at the BTIG Virtual Biotechnology Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the BTIG Virtual Biotechnology Conference, taking place August 9 & 10, 2021.

Jul 12, 2021 04:01 pm ET

Equillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the completion of an End-of-Phase 1 meeting with the U.S. Food and Drug Administration...

Jun 11, 2021 07:00 am ET

Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced positive topline data from the Phase 1b EQUATE study in first-line acute...

Jun 10, 2021 08:00 am ET

Equillium Presents Data on Target Engagement and Modulation of CD6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry

Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced a poster presented yesterday at the CYTO Virtual Interactive Meeting, highlighting a...

Jun 09, 2021 08:00 am ET

Equillium to Present at the JMP Securities Life Sciences Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the JMP Securities Life Sciences Conference, a virtual...

Jun 07, 2021 08:00 am ET

Equillium to Collaborate with Oxford University and Kennedy Institute of Rheumatology to Investigate Role of the CD6-ALCAM Pathway and Itolizumab in Rheumatic Diseases

Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced a translational research collaboration with the Kennedy Institute for Rheumatology and...

Jun 03, 2021 08:00 am ET

Equillium to Host Conference Call Following Presentation of Data from the EQUATE Study in Acute Graft Versus Host Disease at the EHA2021 Virtual Congress of the European Hematology Association on June

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will host a conference call on Friday, June 11, 2021, at 8:00 am ET, following...

May 26, 2021 08:00 am ET

Equillium to Present at the Jefferies Virtual Healthcare Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the Jefferies Virtual Healthcare Conference taking place June...

May 17, 2021 08:00 am ET

Equillium Presents Multiple Posters at the 104th Annual Meeting of the American Association of Immunologists

Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that three posters detailing the novel mechanistic activity of itolizumab were...

May 13, 2021 04:02 pm ET

Equillium Reports First Quarter 2021 Financial Results and Provides Clinical Development Update

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced financial results for the first quarter 2021, and provided an update on its clinical...

May 13, 2021 08:00 am ET

Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that an abstract highlighting positive data from the EQUATE study of itolizumab in...

Apr 27, 2021 08:00 am ET

Equillium Announces Three Abstracts Accepted for Presentation at the 104th Annual Meeting of the American Association of Immunologists

Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that three posters will be presented at VIRTUAL IMMUNOLOGYTM, the 2021 American...

Mar 30, 2021 04:01 pm ET

Equillium Announces Favorable Data From Phase 1b EQUALISE Study in Systemic Lupus Erythematosus Patients

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced favorable topline data from the Type A group of the EQUALISE study in patients with...

Mar 24, 2021 04:05 pm ET

Equillium Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development Update

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced financial results for the fourth quarter and full year 2020, and provided an update...

Mar 15, 2021 08:00 am ET

Equillium Announces Positive Data for Itolizumab in Acute Graft-Versus-Host Disease in Two Presentations at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced positive data supporting the role of itolizumab as a potential treatment for acute...

Mar 02, 2021 08:00 am ET

Equillium to Present at the H.C. Wainwright Global Life Sciences Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the H.C. Wainwright Global Life Sciences Conference. The...

Feb 18, 2021 08:00 am ET

Equillium to Present at the SVB Leerink 10th Annual Global Healthcare Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the SVB Leerink 10th Annual Global Healthcare Conference...

Feb 12, 2021 03:00 pm ET

Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, presented interim data from the EQUATE clinical trial supporting itolizumab’s potential as a...

Feb 09, 2021 08:00 am ET

Equillium Announces the Appointment of Katherine Xu to the Board of Directors

Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Y. Katherine Xu, Ph.D., partner at Decheng Capital, has been appointed to...

Feb 05, 2021 05:35 pm ET

Equillium Announces Closing of $30 Million Registered Direct Offering

Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the closing of its previously announced registered direct offering with life science...

Feb 04, 2021 08:00 am ET

Equillium Announces Pricing of $30 Million Registered Direct Offering

Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that it has entered into a securities purchase agreement with life science...

Jan 22, 2021 08:00 am ET

Equillium Announces Acceptance of Late-Breaking Abstract for Oral Presentation of Interim Data from EQUATE Study in acute GVHD at the 2021 TCT Meetings Digital Experience

Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that interim data from the Phase 1b/2 EQUATE study of itolizumab in acute...

Jan 05, 2021 08:00 am ET

Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference

Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium’s chief executive officer, will present at the H.C....

Dec 21, 2020 08:00 am ET

Equillium Appoints Industry Veteran, Dolca Thomas, M.D. as Executive Vice President of Research & Development and Chief Medical Officer

Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the appointment of Dolca Thomas, M.D., as its executive vice president of research and...

Dec 07, 2020 08:00 am ET

Equillium Presents Translational Data Demonstrating Impact of Itolizumab on Effector T Cell Function at the 2020 American Society of Hematology Annual Meeting and Exposition

Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, presented data over the weekend demonstrating the impact of itolizumab on effector T cell function in...

Nov 30, 2020 08:00 am ET

Equillium to Host Virtual Investor and Analyst Day on December 4, 2020

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that it will host a virtual Investor and Analyst Day on December 4, 2020, from 9:30...

Nov 25, 2020 08:00 am ET

Equillium Provides Itolizumab COVID-19 Program Update

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that due to the rapidly evolving COVID-19 treatment landscape, the company will not...

Nov 10, 2020 04:05 pm ET

Equillium Reports Third Quarter 2020 Financial Results and Business Highlights

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter 2020. “We continue to make significant...

Nov 10, 2020 08:35 am ET

Equillium to Present at Investor Conferences in November 2020

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium’s chief executive officer and Krishna Polu, M.D.,...

Nov 06, 2020 08:35 am ET

Equillium Announces Positive Interim Data of Itolizumab in the First-line Treatment of Acute Graft-Versus-Host Disease

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced positive interim data from the third cohort of the Phase 1b open label, dose...

Nov 04, 2020 08:35 am ET

Equillium to Present Data at the 2020 American College of Rheumatology Meeting Demonstrating CD6 Modulation Improves Kidney and Skin Pathology in Preclinical Models of Systemic Lupus Erythematosus

Equillium, Inc. (Nasdaq: EQ) a clinical stage biotechnology company developing novel immune modifying therapies for severe immune-inflammatory diseases, today announced that data will be presented demonstrating that modulation of the CD6-ALCAM...

Oct 30, 2020 08:30 am ET

Thinking about buying stock in Equillium, Under Armour, Alphabet, Sunesis Pharmaceuticals, or Zendesk?

NEW YORK, Oct. 30, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EQ, UAA, GOOGL, SNSS, and ZEN.

Oct 29, 2020 04:13 pm ET

Equillium Receives FDA Clearance of COVID-19 IND for Phase 3 Trial

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that it has received a Study May Proceed letter from the U.S. Food and Drug...

Sep 17, 2020 04:07 pm ET

Equillium Presented New Data and Insights on the CD6-ALCAM Pathway in Uncontrolled Asthma at the European Respiratory Society International Congress 2020

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that data supporting the CD6-ALCAM pathway as a relevant target for therapeutic...

Sep 15, 2020 08:07 am ET

Equillium Announces Successful Completion of FDA Pre-IND Meeting Enabling Advancement of Itolizumab into a Potential Registration Study as a Treatment for Hospitalized COVID-19 Patients

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced it has completed a pre-Investigational New Drug (IND) meeting with the U.S. Food and...

Sep 03, 2020 04:07 pm ET

Equillium to Present at H.C. Wainwright 22nd Annual Global Investment Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium’s chief...

Aug 18, 2020 04:05 pm ET

Equillium Announces Closing of Public Offering of Common Stock

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the closing of its previously announced underwritten public offering of 5,000,000...

Aug 13, 2020 09:42 pm ET

Equillium Announces Pricing of Public Offering of Common Stock

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the pricing of an underwritten public offering of 5,000,000 shares of common stock at...

Aug 13, 2020 04:02 pm ET

Equillium Announces Proposed Public Offering of Common Stock

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that it intends to offer and sell shares of its common stock in an underwritten...

Aug 12, 2020 08:37 am ET

Equillium Reports Second Quarter 2020 Financial Results and Recent Highlights

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced financial results for the second quarter 2020. “We have made significant progress...

Aug 10, 2020 04:07 pm ET

Equillium Announces Positive Interim Data with Itolizumab in Acute GVHD Study

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced positive interim data from the first two cohorts of the Phase 1b open label, dose...

Jul 30, 2020 04:07 pm ET

Equillium to Present at BTIG Virtual Biotechnology Conference 2020

Jul 14, 2020 10:40 am ET

Thinking about buying stock in Wells Fargo, IMV Inc, Nokia, Equillium Inc, or Marathon Oil Corp?

NEW YORK, July 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WFC, IMV, NOK, EQ, and MRO.

Jul 13, 2020 03:30 am ET

Clinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that as reported by its partner, Biocon Limited, a clinical trial conducted in India...

Jun 03, 2020 09:00 am ET

47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th

NEW YORK, NY / ACCESSWIRE / June 3, 2020 / The Virtual Summer Summit will take place on June 9th-12th, connecting 47 presenting small and microcap companies with distinguished investors from around the globe. A full list of issuers are listed below along with webcasting links to view presentations.

May 21, 2020 04:07 pm ET

Equillium to Present at Jefferies Virtual Healthcare Conference

May 13, 2020 04:07 pm ET

Equillium Reports First Quarter 2020 Financial Results

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced financial results for the first quarter...

May 07, 2020 04:07 pm ET

Equillium to Present at 2020 RBC Capital Markets Virtual Global Healthcare Conference

Mar 30, 2020 04:07 pm ET

Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital

Mar 26, 2020 04:07 pm ET

Equillium Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update

Feb 27, 2020 04:14 pm ET

Equillium Strengthens Leadership Team with Key Appointments

Feb 13, 2020 04:07 pm ET

Equillium to Present at 9th Annual SVB Leerink Global Healthcare Conference

Jan 29, 2020 04:07 pm ET

Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versus-Host Disease Treated with Itolizumab at the Transplantatio

Dec 12, 2019 07:00 am ET

Equillium & Biocon Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand

Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, and Biocon Ltd (BSE code: 532523, NSE: BIOCON), an...

Dec 09, 2019 04:10 pm ET

Equillium Granted U.S. FDA Fast Track Designation for Itolizumab for the Treatment of Lupus Nephritis

Nov 26, 2019 04:07 pm ET

Equillium to Present Translational Data on Itolizumab for Acute Graft-Versus-Host Disease at 61st American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 15, 2019 08:05 am ET

Equillium Featured in Panel Discussion at Capital Markets Day for Kidney Health

Nov 12, 2019 04:07 pm ET

Equillium Announces Leadership Updates

Nov 12, 2019 04:05 pm ET

Equillium Reports Third Quarter 2019 Financial Results and Recent Highlights

Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the...

Nov 07, 2019 04:07 pm ET

Equillium to Present at Investor Conferences in November 2019

Nov 06, 2019 08:05 am ET

Equillium to Present New Data and Insights on the CD6-ALCAM Pathway in Lupus Nephritis at ACR 2019

Oct 31, 2019 09:14 am ET

Orgenesis Appoints Bala S. Manian to its Scientific Advisory Board

Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services through its subsidiary MTH Global, Inc., as well as localized...

Oct 01, 2019 04:05 pm ET

Equillium Announces Initiation of the EQUALISE Phase 1b Clinical Trial of Itolizumab for Patients with Lupus Nephritis and Provides Business Update

Sep 17, 2019 04:07 pm ET

Equillium to Host Business Update Call on October 1, 2019

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders will be hosting a call with shareholders and the...

Aug 27, 2019 04:07 pm ET

Equillium to Present at H. C. Wainwright 21st Annual Global Investment Conference

Aug 12, 2019 04:07 pm ET

Equillium Reports Second Quarter 2019 Financial Results and Recent Highlights

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial...

Jul 10, 2019 08:07 am ET

Equillium Announces Initiation of the EQUIP Phase 1b Clinical Trial of Itolizumab for Patients with Uncontrolled Asthma

May 23, 2019 04:07 pm ET

Equillium to Present at Jefferies 2019 Healthcare Conference

May 13, 2019 04:07 pm ET

Equillium Reports First Quarter 2019 Financial Results and Recent Highlights

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial...

May 06, 2019 08:30 am ET

Equillium Expands Scientific and Clinical Advisory Team

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced it has...

Apr 16, 2019 04:07 pm ET

Equillium to Present at Solebury Trout Class of 2018 Biotech IPO Investor Day

Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that Bruce Steel, Equillium’s president and chief business officer, will present at the Solebury Trout Class of...

Mar 28, 2019 04:07 pm ET

Equillium to Present at H.C. Wainwright Global Life Sciences Conference

Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that Dan Bradbury, Equillium’s chairman and chief executive officer, will present at the H.C. Wainwright Global...

Mar 27, 2019 04:07 pm ET

Equillium Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights

Feb 26, 2019 04:07 pm ET

Equillium Announces Plan to Develop EQ001 for the Treatment of Lupus Nephritis

Feb 21, 2019 04:07 pm ET

Equillium to Present at Leerink Partners Global Healthcare Conference

Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immune-inflammatory disorders, announced today that Bruce Steel, Equillium’s president and chief business officer, will present at the Leerink Partners 8th...

Feb 19, 2019 04:07 pm ET

Equillium to Host Business Update Call on February 26

Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immune-inflammatory disorders, will be hosting a call with shareholders and the investment community to provide a business update on Tuesday, February 26, 2019....

Feb 07, 2019 08:08 am ET

Equillium Granted U.S. FDA Orphan Drug Designations for EQ001 (itolizumab) for both the Prevention and Treatment of Acute Graft-Versus-Host Disease

Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designations for EQ001 for both the...

Dec 19, 2018 08:06 am ET

Ad blocking detected

Equillium, Inc. - Common Stock (OQ:EQ)

Business Focus: N/A